Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Medical therapy for acromegaly.

¹Department of Clinical Medicine, New York University School of Medicine, New York, USA.

Endocrinology and Metabolism Clinics of North America

|April 20, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Minimally invasive thoracic corpectomy and anterior fusion in a patient with metastatic disease: case report and review of the literature.

Minimally invasive neurosurgery : MIN·2009

Same author

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

Diabetologia·2008

Same author

Percutaneous axial lumbar interbody fusion (AxiaLIF) of the L5-S1 segment: initial clinical and radiographic experience.

Minimally invasive neurosurgery : MIN·2008

Same author

Octreotide as primary therapy for acromegaly.

The Journal of clinical endocrinology and metabolism·1998

Same author

Acromegaly.

Current therapy in endocrinology and metabolism·1997

Same author

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

The Journal of clinical endocrinology and metabolism·1995

Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026

Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026

Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026

Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026

Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026

Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026

See all related articles

Somatostatin analogues and dopamine agonists treat acromegaly, with analogues being more effective. Surgery is preferred for microadenomas, while medical therapy is an option for macroadenomas or non-surgical candidates.

Area of Science:

Endocrinology
Oncology

Background:

Acromegaly is a disorder caused by excess growth hormone (GH).
Somatostatin analogues and dopamine agonists are primary medical treatments.
Treatment decisions involve drug efficacy, side effect profiles, and patient factors.

Purpose of the Study:

To review the current evidence for medical therapy in acromegaly.
To compare the efficacy of somatostatin analogues and dopamine agonists.
To discuss the role of medical therapy as primary versus secondary treatment.

Main Methods:

Literature review of studies on somatostatin analogues and dopamine agonists for acromegaly.
Analysis of data on treatment efficacy, tumor shrinkage, and biochemical cure.
Comparison of medical therapy with surgical outcomes.

Related Experiment Videos

Main Results:

Somatostatin analogues normalize IGF-1 in 60-65% of patients and reduce GH levels, but tumor shrinkage is limited to 40%.
Surgery offers a higher chance of cure for microadenomas (>=70%).
For macroadenomas with low surgical resection probability, somatostatin analogues are a viable primary option.

Conclusions:

Somatostatin analogues are generally more effective than dopamine agonists for acromegaly.
Surgery remains the preferred primary treatment for GH-secreting microadenomas.
Medical therapy is indicated for patients refusing surgery, poor surgical candidates, or those with macroadenomas where complete resection is unlikely.